Skip to main content
HairCited

ミノキシジル 男性型・女性型脱毛症(AGA)

A

合計41,495名の参加者を対象とした191件の研究(メタアナリシス19件、RCT 21件を含む)に基づく。191件中159件の研究で肯定的な効果が示されている。

<\/script>\n
`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'ingredient\u003Dminoxidil\u0026condition\u003Dandrogenetic\u002Dalopecia'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

結論

Minoxidil is strongly supported by extensive research as an effective option that may help promote hair regrowth in people with androgenetic alopecia.

  • 191 studies with over 41,000 participants — one of the most researched hair loss ingredients
  • 83% of studies show positive effects on hair regrowth and density
  • Both topical and oral forms are supported by meta-analyses and RCTs
  • Recent expert consensus guidelines support its use as a first-line option

Key Study Findings

review
Oral Minoxidil for Alopecia Treatment: Risks, Benefits, and Recommendations.
Dose: Oral minoxidil: women 1.25 mg/day starting dose (range 0.625-5 mg/day); men 2.5 mg/day (range 1.25-5 vs: Placebo 効果: Comparable efficacy to topical minoxidil; hypertrichosis 24%, shedding 16-22%, peripheral edema 2% None
Review
Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments.
Dose: None vs: None Outcome: None 効果: None None

対象集団: women with androgenetic alopecia (female pattern hair loss)

Other
Low-dose oral minoxidil (LDOM) and topical minoxidil: consensus recommendations for managing male and female pattern …
Dose: MPHL: 1.25-2.5 mg/day; FPHL: 0.625-1.25 mg/day vs: None Outcome: consensus recommendations for managing pattern hair loss 効果: None None

対象集団: hair transplant patients with male and female pattern hair loss (Delphi panel consensus)

non-randomized controlled trial n=60 16 weeks Open-label
Clinical Efficacy and Mechanisms of Microneedling Alone or Combined With Drugs in the Treatment of …
Dose: Mild group: microneedling alone (8 weeks); Moderate group: microneedling + 5% minoxidil (12 weeks); vs: Placebo 効果: All groups showed significant decrease in HLSS and increase in hair density post-treatment (p<0.001) p<0.001
Case Reports n=1 Open-label
Plica Neuropathica (Polonica) Secondary to Diffuse Alopecia: A Case Report and Literature Review.
Dose: None vs: None Outcome: None 効果: None None

対象集団: 62-year-old female with diffuse alopecia and plica neuropathica

review
Antiandrogen therapy for the treatment of female pattern hair loss: A clinical review of current …
Dose: varies by agent and study vs: Placebo 効果: variable; oral antiandrogens demonstrate some efficacy; topical antiandrogens possibly fewer systemi None

Key Statistics

299

研究数

68291

参加者数

Positive

A

グレード

Referenced Papers

Journal of the … 2026
Aesthetic plastic surgery 2025 14 件の引用
Anais brasileiros de … 2025 7 件の引用
Drug design, development … 2025 7 件の引用
Acta dermato-venereologica 2025 4 件の引用
European journal of … 2025 3 件の引用
Australian prescriber 2025 2 件の引用
Journal of cutaneous … 2025 2 件の引用
Acta dermatovenerologica Alpina, … 2025 2 件の引用
International journal of … 2025 1 件の引用
Journal of clinical … 2025 1 件の引用
Skin appendage disorders 2025 1 件の引用
Nature reviews. Disease … 2025
Archives of dermatological … 2025
Annals of dermatology 2025
International journal of … 2024 39 件の引用
Indian journal of … 2024 14 件の引用
Journal of cosmetic … 2024 11 件の引用
Journal of clinical … 2024 10 件の引用
Facial plastic surgery … 2024 8 件の引用
Photodermatology, photoimmunology & … 2024 8 件の引用
American family physician 2024 8 件の引用
Skin health and … 2024 7 件の引用
International journal of … 2024 5 件の引用
SAGE open medical … 2024 3 件の引用
Vestnik oftalmologii 2024 1 件の引用
Drugs 2023 221 件の引用
JAAD international 2023 80 件の引用
Clinical, cosmetic and … 2023 58 件の引用
American journal of … 2023 41 件の引用
Anais brasileiros de … 2023 29 件の引用
Skin appendage disorders 2023 27 件の引用
Archives of dermatological … 2023 16 件の引用
Journal der Deutschen … 2023 5 件の引用
International journal of … 2023 5 件の引用
Journal of cosmetic … 2023 3 件の引用
BMJ case reports 2023 2 件の引用
Clinics in plastic … 2023 1 件の引用
International journal of … 2023 1 件の引用
The Journal of … 2022 170 件の引用
Faculty reviews 2022 44 件の引用
Dermatology and therapy 2022 43 件の引用
Dermatologic therapy 2022 41 件の引用
Journal of cosmetic … 2022 35 件の引用
Journal of cosmetic … 2022 7 件の引用
Cureus 2022 3 件の引用
Facial plastic surgery … 2022
Journal of cutaneous … 2021 44 件の引用
Journal of the … 2021 42 件の引用
Actas dermo-sifiliograficas 2021 3 件の引用
Expert opinion on … 2020 147 件の引用
American journal of … 2020 127 件の引用
International journal of … 2020 58 件の引用
Dermatologic therapy 2020 34 件の引用
Indian dermatology online … 2020 31 件の引用
American journal of … 2020 24 件の引用
Dermatologic clinics 2020 15 件の引用
Facial plastic surgery … 2020 15 件の引用
Alternative therapies in … 2020 11 件の引用
Drug design, development … 2019 320 件の引用
Journal of cosmetic … 2019 100 件の引用
American journal of … 2019 84 件の引用
Expert opinion on … 2019 34 件の引用
Bioscience, biotechnology, and … 2019 9 件の引用
International journal of … 2018 129 件の引用
Journal of the … 2018 114 件の引用
Indian journal of … 2018 79 件の引用
Lasers in medical … 2018 75 件の引用
Dermatologic therapy 2018 63 件の引用
Australian journal of … 2018 8 件の引用
American family physician 2017 141 件の引用
JAMA dermatology 2017 121 件の引用
Current clinical pharmacology 2017 62 件の引用
Lasers in medical … 2017 43 件の引用
Actas dermo-sifiliograficas 2017 17 件の引用
BMJ case reports 2017 6 件の引用
Deutsches Arzteblatt international 2016 99 件の引用
The Cochrane database … 2016 18 件の引用
The Medical clinics … 2015 66 件の引用
Seminars in cutaneous … 2015 27 件の引用
Current problems in … 2015 8 件の引用
Der Internist 2015
Lasers in surgery … 2014 243 件の引用
Journal of cutaneous … 2014 168 件の引用
Expert opinion on … 2014 57 件の引用
Skin therapy letter 2014 29 件の引用
Journal of drugs … 2014 26 件の引用
Giornale italiano di … 2014 8 件の引用
Giornale italiano di … 2014
Indian journal of … 2013 196 件の引用
Dermatologic clinics 2013 78 件の引用
Journal of cosmetic … 2013 62 件の引用
International journal of … 2013 61 件の引用
Indian journal of … 2013 16 件の引用
Facial plastic surgery … 2013 16 件の引用
International journal of … 2013
Skin therapy letter 2012 100 件の引用
The Cochrane database … 2012 15 件の引用
Expert opinion on … 2010 264 件の引用
Current opinion in … 2009 54 件の引用
Seminars in cutaneous … 2009 4 件の引用
American family physician 2009
Current opinion in … 2008 31 件の引用
Nihon rinsho. Japanese … 2008 6 件の引用
Endocrinology and metabolism … 2007 33 件の引用
The Australasian journal … 2007 32 件の引用
Clinical interventions in … 2007
Acta dermatovenerologica Alpina, … 2005
Annual review of … 2004 664 件の引用
Revue medicale de … 2004
The journal of … 2003 102 件の引用
Praxis 2003 28 件の引用
American family physician 2003 2 件の引用
American family physician 2003
Clinical and experimental … 2002 61 件の引用
Therapeutische Umschau. Revue … 2002 4 件の引用
American journal of … 2000 18 件の引用
Southern medical journal 2000
International journal of … 1999 16 件の引用
Journal of cutaneous … 1999
Journal of the … 1999
International journal of … 1999
American family physician 1999
Dermatologic clinics 1998 121 件の引用
Annales de dermatologie … 1997
Journal of the … 1984

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

一般的な使用量

topical:
2-5% solution, twice daily

上限量: 5% topical solution

研究で検討された用量

用量 期間 効果 N
Oral minoxidil: women 1.25 mg/day starting dose (range 0.625-5 mg/day); men 2.5 mg/day (range 1.25-5 -- Positive --
None -- Neutral --
MPHL: 1.25-2.5 mg/day; FPHL: 0.625-1.25 mg/day -- Positive --
Mild group: microneedling alone (8 weeks); Moderate group: microneedling + 5% minoxidil (12 weeks); 16 weeks Positive 60
None -- Mixed 1
varies by agent and study -- Positive --
None -- Positive --
None -- Mixed --

推奨摂取タイミング: Apply to dry scalp morning and evening, at least 4 hours before bed

Safety & Side Effects

報告されている副作用

  • Scalp irritation and dryness
  • Initial shedding phase (first 2-8 weeks)
  • Unwanted facial hair growth (especially in women)
  • Dizziness or lightheadedness (rare with topical use)
  • Heart palpitations (rare, more common with oral form)

既知の相互作用

  • Antihypertensive medications (additive blood pressure lowering)
  • Topical corticosteroids (may increase absorption)
  • Retinoids (tretinoin may enhance penetration and side effects)

耐容上限摂取量: 5% topical solution

サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。

Frequently Asked Questions

Does ミノキシジル help with 男性型・女性型脱毛症(AGA)?
Based on 299 studies with 68,291 participants, there is strong evidence from multiple clinical trials that ミノキシジル may support 男性型・女性型脱毛症(AGA) management. Our evidence grade is A (Strong Evidence).
How much ミノキシジル should I take for 男性型・女性型脱毛症(AGA)?
Studies have used various dosages. A commonly studied range is 2-5% solution, twice daily. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of ミノキシジル?
Reported side effects may include Scalp irritation and dryness, Initial shedding phase (first 2-8 weeks), Unwanted facial hair growth (especially in women), Dizziness or lightheadedness (rare with topical use). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for ミノキシジル and 男性型・女性型脱毛症(AGA)?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 299 peer-reviewed studies with 68,291 total participants. The overall direction of effect is positive.

Related Evidence

FDAに関する免責事項: これらの記述は米国食品医薬品局(FDA)による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。